Diseases which may be prevented or cured by means of therapeutic fasting and caloric restriction  
(experimental and clinical evidence: click to see scientific report)

» arthritis rheumatoid
» asthma
» cardiovascular diseases
» cholecystitis and gout
» chronic fatigue syndrome
» diabetes
» digestive system diseases
» epilepsy
» glomerulonephritis
» hypertension
» infections
» infertility
» Low immunity
» neurodegenerative disorders
» obesity
» ovarian tumors
» pancreatitis
» psoriasis
» psychiatric disorders
» respiratory system diseases
» skin disorders
» spinal column diseases
» thrombophlebitis
» tumours, cancer
» uterine fibroids
» Complications in fasting
» Safety of fating
» sarcoidosis
Anti-Aging Therapy
Fasting / low-calorie program on Adriatic Sea Coast
Kidney cancer drug gets FDA approval
 
 21.12.2007
The Food and Drug Administration on Tuesday approved Nexavar, the first new drug for advanced kidney cancer in more than a decade.
Nexavar, which is marketed by Bayer, does not cure cancer. And only 2% of patients saw their cancers shrink by 30%, a traditional measure of a cancer drug's effectiveness, says Ronald Bukowski, director of experimental therapeutics at The Cleveland Clinic Taussig Cancer Center, who led studies of Nexavar.
But Nexavar does stabilize kidney cancer and improves quality of life. Patients who took the pill went nearly six months before their cancer progressed; those who took placebos saw their tumors advance in less than three months, according to the FDA.
That makes the drug a "major advance" in the treatment of renal cell carcinoma, the most common type of kidney cancer, says Richard Pazdur, who leads the oncology drug products office in the FDA's Center for Drug Evaluation and Research.
Pazdur noted that Nexavar, a pill, is easier on patients than standard treatments, such as interferon and interleukin-2, which are typically given in an intensive care unit.
Although about 40% of patients on Nexavar experience side effects such as diarrhea, serious problems are rare, according to the FDA.
Nexavar fights cancer by shriveling up the blood vessels that feed tumors and by turning off runaway growth signals inside the cells, Bukowski says.
About half of the 36,000 cases of kidney cancer a year are advanced renal cell carcinomas, he says.

«« Back